RevenueShares Ultra Dividend ETF
Taking Stock of Radius Health’s Licensing Agreements
The market has responded very positively to Radius Health’s recent performance. In the past month, Radius stock has generated a 28% return for its shareholders.
A Strong Pipeline of Drugs Bodes Well for Radius Health
The drug candidates in Radius Health’s (RDUS) pipeline include an investigational abaloparatide transdermal patch for possible use in treating women with postmenopausal osteoporosis.
Analysts’ Ratings for Radius Health and Its Peers in January
In April 2017, Radius received FDA approval for its first commercial product, Tymlos. Tymlos was approved for the treatment of postmenopausal women with osteoporosis at a high risk for fracture.